Table 2.
Tissue concentrations of budesonide, budesonide oleate and fluticasone propionate, obtained 1–43 h after a single inhalation
| Mean tissue concentrations, pmol g−1 | Compound | ||
|---|---|---|---|
| [number of values above LOQ] (range) | Budesonide | Budesonide oleate | Fluticasone propionate |
| Interval 1–6 h (n = 6) | |||
| Brush | 1.31 [1] (BQL-4.73) | 0.84 [1] (BQL-3.48) | 0.82 [1] (BQL-1.78) |
| Central | 17.15 [5] (BQL-61.70) | 17.73 [6] (2.41–58.60) | 87.27 [5] (BQL-459.00) |
| Peripheral | 4.33 [5] (BQL-14.60) | 3.96 [6] (2.02–9.34) | 18.49 [6] (2.07–40.30) |
| Muscle | 3.08 [6] (1.68–6.45) | BQL [0] | BQL [0] |
| Interval 6–12 h (n = 3) | |||
| Brush | BQL [0] | BQL [0] | 173.48 [2] (BQL-506.00) |
| Central | 0.86 [1] (BQL-1.33) | 1.85 [3] (0.64–2.88) | 5.99 [2] (BQL-12.00) |
| Peripheral | 1.21 [1] (BQL-2.37) | 2.41 [3] (0.98–4.74) | 10.47 [3] (3.76–21.20) |
| Muscle | 0.98 [1] (BQL-1.70) | BQL [0] | BQL [0] |
| Interval 12–18 h (n = 5) | |||
| Brush | BQL [0] | BQL [0] | 2.00 [2] (BQL-6.84) |
| Central | BQL [0] | 2.20 [0] (BQL-4.35) | 27.80 [4] (BQL-96.30) |
| Peripheral | BQL [0] | 2.24 [5] (0.68–3.31) | 8.56 [4] (BQL-26.70) |
| Muscle | BQL [0] | BQL [0] | BQL [0] |
| Interval 18–24 h (n = 6) | |||
| Brush | BQL [0] | BQL [0] | BQL [0] |
| Central | BQL [0] | 1.94 [4] (BQL-5.25) | 0.94 [1] (BQL-2.51) |
| Peripheral | BQL [0] | 2.18 [6] (0.98–4.76) | 2.06 [3] (BQL-4.59) |
| Muscle | BQL [0] | BQL [0] | BQL [0] |
| Interval >24 h (n = 2) | |||
| Brush | BQL [0] | BQL [0] | BQL [0] |
| Central | BQL [0] | BQL [0] | BQL [0] |
| Peripheral | BQL [0] | 0.50 [1] (BQL-0.68) | BQL [0] |
| Muscle | BQL [0] | BQL [0] | BQL [0] |
BQL, below the lower limit of quantification.